Mode
Text Size
Log in / Sign up

Systematic review evaluates SDR, ITB, DBS, and other interventions for functional outcomes in ambulatory children with cerebral palsy.

Systematic review evaluates SDR, ITB, DBS, and other interventions for functional outcomes in ambula…
Photo by Ben Maffin / Unsplash
Key Takeaway
Consider multidisciplinary evaluation for treatment selection in ambulatory cerebral palsy patients.

This systematic review assessed multiple interventions for ambulatory children with cerebral palsy, including those with dystonia-predominant phenotypes or mixed presentations. The interventions evaluated included Selective dorsal rhizotomy (SDR), combined dorsal-ventral rhizotomy, peripheral neurectomies, intrathecal baclofen (ITB), deep brain stimulation (DBS) targeting the globus pallidus internus, emerging cerebellar DBS, spinal cord stimulation (SCS), and focused ultrasound. Primary outcomes focused on functional status, motor function, quality of life, muscle tone, walking speed, and spasticity reduction.

Surgical and neuromodulation approaches demonstrated varying degrees of efficacy. SDR was identified as a novel treatment option for spastic diplegia in ambulatory children. Combined dorsal-ventral rhizotomy showed promise for mixed presentations. Peripheral neurectomies provided targeted management with sustained improvements in muscle tone and walking speed for focal spasticity. Intrathecal baclofen (ITB) effectively reduced spasticity and dystonia, although scoliosis progression requires monitoring with this therapy. DBS targeting the globus pallidus internus demonstrated efficacy in dystonia-predominant cerebral palsy, with younger patients showing greater improvement. Emerging cerebellar DBS approaches show early promise for spasticity and mixed presentations.

Spinal cord stimulation (SCS) may benefit select patients with spasticity or painful dystonia, though evidence remains limited. Focused ultrasound represents a novel noninvasive ablative option currently under investigation. Safety data indicated infection rates associated with ITB, while serious adverse events and discontinuations were not reported. The review noted that treatment selection requires multidisciplinary evaluation considering movement disorder phenotype, functional goals, patient age, and family factors.

Key takeaway: Consider multidisciplinary evaluation for treatment selection in ambulatory cerebral palsy patients.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
Cerebral palsy (CP) affects 1.5–2.5 per 1,000 live births and manifests as diverse movement disorders including spasticity, dystonia, and mixed phenotypes that significantly impact motor function and quality of life. This review examines surgical and neuromodulatory interventions for medically refractory CP-associated movement disorders. Selective dorsal rhizotomy (SDR) offers a novel treatment option for spastic diplegia in ambulatory children (GMFCS II-III), with combined dorsal-ventral rhizotomy showing promise for mixed presentations. Peripheral neurectomies provide targeted focal spasticity management with sustained improvements in muscle tone and walking speed. Intrathecal baclofen (ITB) effectively reduces spasticity and dystonia through programmable drug delivery, though infection rates and potential scoliosis progression require monitoring. Deep brain stimulation (DBS) targeting the globus pallidus internus demonstrates efficacy for dystonia-predominant CP, with younger patients showing greater improvement. Emerging cerebellar DBS approaches show early promise for spasticity and mixed presentations. Spinal cord stimulation (SCS) may benefit select patients with spasticity or painful dystonia, though evidence remains limited. Focused ultrasound represents a novel noninvasive ablative option currently under investigation. Treatment selection requires multidisciplinary evaluation considering movement disorder phenotype, functional goals, patient age, and family factors. As understanding of CP pathophysiology advances, mechanism-based, individualized treatment algorithms will increasingly optimize functional outcomes for this heterogeneous patient population.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.